I Hate Dialysis Message Board
Welcome, Guest. Please login or register.
November 27, 2024, 12:28:06 AM

Login with username, password and session length
Search:     Advanced search
532606 Posts in 33561 Topics by 12678 Members
Latest Member: astrobridge
* Home Help Search Login Register
+  I Hate Dialysis Message Board
|-+  Dialysis Discussion
| |-+  Dialysis: News Articles
| | |-+  Columbia Professor Is Linked to Insider Trading Case
0 Members and 1 Guest are viewing this topic. « previous next »
Pages: [1] Go Down Print
Author Topic: Columbia Professor Is Linked to Insider Trading Case  (Read 1389 times)
Meinuk
Sr. Member
****
Offline Offline

Gender: Female
Posts: 891


« on: September 21, 2011, 09:07:55 AM »

http://www.nytimes.com/2011/09/17/health/17insider.html?_r=1&scp=1&sq=kidney%20drug&st=cse

I'm not going to post the whole article.  In my opinion, essentially, it is about greed.  My take on all of this is that the more that we see what is going on behind the scenes at these drug companies, we will find out how our health is nothing but a catalyst for people to make money...

Really? "The drug costs more than $23,000 a vial; Questcor, betting on its value, had raised the price from $1,650 a vial in 2007"  really?  From $1,650 to $23,000???   And these people sleep at night?  Well, they do sleep at night on Duxiana Beds with Pratesi Sheets.

And we wonder why our insurance premiums are so high... (if our insurance would pay for the drug at all - a pity, research showed that it helped 9/11 people with "a certain type of nephrotic syndrom".)

 From:  Columbia Professor Is Linked to Insider Trading Case  (Bolding my emphasis).

Quote
The study found that 9 of 11 of the patients with a certain type of nephrotic syndrome responded well to treatment. In doing so, the study has helped transform the drug, called H.P. Acthar Gel, from the status of an orphan to that of a potential blockbuster.

Questcor told investors this month that the expensive, injectable drug could have $1 billion sales for the niche condition Dr. Bomback studied. The drug costs more than $23,000 a vial; Questcor, betting on its value, had raised the price from $1,650 a vial in 2007. The drug is also sold for ultrarare infant spasms and select multiple sclerosis patients.


link to the study:  http://www.dovepress.com/treatment-of-nephrotic-syndrome-with-adrenocorticotropic-hormone-acth--a6667
« Last Edit: September 21, 2011, 09:09:28 AM by Meinuk » Logged

Research Dialysis Units:  http://projects.propublica.org/dialysis/

52 with PKD
deceased donor transplant 11/2/08
nxstage 10/07 - 11/08;  30LS/S; 20LT/W/R  @450
temp. permcath:  inserted 5/07 - removed 7/19/07
in-center hemo:  m/w/f 1/12/07
list: 6/05
a/v fistula: 5/05
NxStage training diary post (10/07):  http://ihatedialysis.com/forum/index.php?topic=5229.0
Newspaper article: Me dialyzing alone:  http://ihatedialysis.com/forum/index.php?topic=7332.0
Transplant post 11/08):  http://ihatedialysis.com/forum/index.php?topic=10893.msg187492#msg187492
Fistula removal post (7/10): http://ihatedialysis.com/forum/index.php?topic=18735.msg324217#msg324217
Post Transplant Skin Cancer (2/14): http://ihatedialysis.com/forum/index.php?topic=30659.msg476547#msg476547

“To doubt everything or to believe everything are two equally convenient solutions; both dispense with the necessity of thought.” - Henri Poincare
Pages: [1] Go Up Print 
« previous next »
 

Powered by MySQL Powered by PHP SMF 2.0.17 | SMF © 2019, Simple Machines | Terms and Policies Valid XHTML 1.0! Valid CSS!